Antiendothelial αvβ3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 8, 2016, Pages 1517-1524

  Santoso, Sentot ^a   Wihadmadyatami, Hevi ^a,b   Bakchoul, Tamam ^c   Werth, Silke ^a   Al Fakhri, Nadia ^d   Bein, Gregor ^a,d   Kiefel, Volker ^e   Zhu, Jieqing ^f   Newman, Peter J ^f   Bayat, Behnaz ^a   Sachs, Ulrich J ^a,d  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

antibodies; endothelial cells; intracranial hemorrhages; reactive oxygen species; thrombocytopenia, neonatal alloimmune

Indexed keywords

ANTI HUMAN PLATELET ANTIGEN 1A ANTIBODY; CASPASE 3; CASPASE 7; REACTIVE OXYGEN METABOLITE; RECEPTOR ANTIBODY; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG; VITRONECTIN; VITRONECTIN RECEPTOR; 1A ALLOANTIGEN, HUMAN; AUTOANTIBODY; CASP3 PROTEIN, HUMAN; CASP7 PROTEIN, HUMAN;

ABSORPTION; ANTIGEN BINDING; APOPTOSIS; ARTICLE; BRAIN HEMORRHAGE; CELL ADHESION; COHORT ANALYSIS; ENDOTHELIUM CELL; ENZYME ACTIVATION; IMMUNOASSAY; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; SEROLOGY; ANGIOGENESIS; ANIMAL; ANTIBODY SPECIFICITY; CASE CONTROL STUDY; CHO CELL LINE; CRICETULUS; FEMALE; FETOMATERNAL TRANSFUSION; GENETIC TRANSFECTION; GENETICS; GESTATIONAL AGE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; NEWBORN; PATHOLOGY; PREGNANCY; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, HUMAN PLATELET; APOPTOSIS; AUTOANTIBODIES; CASE-CONTROL STUDIES; CASPASE 3; CASPASE 7; CELL ADHESION; CHO CELLS; CRICETULUS; ENDOTHELIAL CELLS; FEMALE; GESTATIONAL AGE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFANT, NEWBORN; INTEGRIN ALPHAVBETA3; INTRACRANIAL HEMORRHAGES; MALE; MATERNAL-FETAL EXCHANGE; NEOVASCULARIZATION, PHYSIOLOGIC; PREGNANCY; REACTIVE OXYGEN SPECIES; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE; TRANSFECTION;

EID: 84973532000     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307281     Document Type: Article

References (36)

1. Mueller-Eckhardt C, Kiefel V, Grubert A, Kroll H, Weisheit M, Schmidt S, Mueller-Eckhardt G, Santoso S. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1:363-366
2. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007;110:833-839. doi: 10. 1182/blood-2006-08-040121
3. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol. 2001;41:45-55
4. Bussel J. Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost. 2009;7(suppl 1):253-257. doi: 10. 1111/j. 1538-7836. 2009. 03380. x
5. Thude H, Schorner U, Helfricht C, Loth M, Maak B, Barz D. Neonatal alloimmune thrombocytopenia caused by human leucocyte antigen-B27 antibody. Transfus Med. 2006;16:143-149. doi: 10. 1111/j. 1365-3148. 2006. 00634. x
6. Kroll H, Penke G, Santoso S. Functional heterogeneity of alloantibodies against the human platelet antigen (HPA)-1a. Thromb Haemost. 2005;94:1224-1229. doi: 10. 1160/TH05-03-0159
7. Birchall JE, Murphy MF, Kaplan C, Kroll H; European Fetomaternal Alloimmune Thrombocytopenia Study Group. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol. 2003;122:275-288
8. Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang. 2003;84:318-325
9. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest. 1989;83:1778-1781. doi: 10. 1172/JCI114082
10. Bennett JS, Berger BW, Billings PC. The structure and function of platelet integrins. J Thromb Haemost. 2009;7(suppl 1):200-205. doi: 10. 1111/j. 1538-7836. 2009. 03378. x
11. Cheresh DA, Smith JW, Cooper HM, Quaranta V. A novel vitronectin receptor integrin (alpha v beta x) is responsible for distinct adhesive properties of carcinoma cells. Cell. 1989;57:59-69
12. Leeksma OC, Giltay JC, Zandbergen-Spaargaren J, Modderman PW, van Mourik JA, von dem Borne AE. The platelet alloantigen Zwa or PlA1 is expressed by cultured endothelial cells. Br J Haematol. 1987;66:369-373
13. Giltay JC, Leeksma OC, von dem Borne AE, van Mourik JA. Alloantigenic composition of the endothelial vitronectin receptor. Blood. 1988;72:230-233
14. van Gils JM, Stutterheim J, van Duijn TJ, Zwaginga JJ, Porcelijn L, de Haas M, Hordijk PL. HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. Mol Immunol. 2009;46:406-415. doi: 10. 1016/j. molimm. 2008. 10. 015
15. Radder CM, Beekhuizen H, Kanhai HH, Brand A. Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells. Clin Exp Immunol. 2004;137:216-222. doi: 10. 1111/j. 1365-2249. 2004. 02496. x
16. Yougbaré I, Lang S, Yang H, et al. Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage. J Clin Invest. 2015;125:1545-1556. doi: 10. 1172/JCI77820
17. Tiller H, Husebekk A, Skogen B, Kjeldsen-Kragh J, Kjaer M. True risk of fetal/neonatal alloimmune thrombocytopenia in subsequent pregnancies: a prospective observational follow-up study. BJOG. 2016;123:738-744. doi: 10. 1111/1471-0528. 13343
18. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol. 2001;13:555-562
19. Li AE, Ito H, Rovira II, Kim KS, Takeda K, Yu ZY, Ferrans VJ, Finkel T. A role for reactive oxygen species in endothelial cell anoikis. Circ Res. 1999;85:304-310
20. Bernardini A, Brockmeier U, Metzen E, Berchner-Pfannschmidt U, Harde E, Acker-Palmer A, Papkovsky D, Acker H, Fandrey J. Measurement of ROS levels and membrane potential dynamics in the intact carotid body ex vivo. Adv Exp Med Biol. 2015;860:55-59. doi: 10. 1007/978-3-319-18440-1-7
21. Bussel JB, Berkowitz RL, Hung C, Kolb EA, Wissert M, Primiani A, Tsaur FW, Macfarland JG. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol. 2010;203:135. e1-135. 14. doi: 10. 1016/j. ajog. 2010. 03. 011
22. Valentin N, Visentin GP, Newman PJ. Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response. Blood. 1995;85:3028-3033
23. Honda S, Honda Y, Bauer B, Ruan C, Kunicki TJ. The impact of threedimensional structure on the expression of PlA alloantigens on human integrin beta 3. Blood. 1995;86:234-242
24. Liu LX, Nardi MA, Casella JF, Karpatkin S. Inhibition of binding of anti-PLA1 antibodies to platelets with monoclonal antibody LK-4. Evidence for multiple PLA1 receptor sites on platelet GPIIIa. Blood. 1996;88:3601-3607
25. Allen DL, Abrahamsson S, Murphy MF, Roberts DJ. Human platelet antigen 1a epitopes are dependent on the cation-regulated conformation of integrin α(IIb)β(3) (GPIIb/IIIa). J Immunol Methods. 2012;375:166-175. doi: 10. 1016/j. jim. 2011. 10. 008
26. Erdreich-Epstein A, Tran LB, Cox OT, Huang EY, Laug WE, Shimada H, Millard M. Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways. Blood. 2005;105:4353-4361. doi: 10. 1182/blood-2004-08-3098
27. Wang WJ. Acurhagin-C, an ECD disintegrin, inhibits integrin alphavbeta3-mediated human endothelial cell functions by inducing apoptosis via caspase-3 activation. Br J Pharmacol. 2010;160:1338-1351. doi: 10. 1111/j. 1476-5381. 2010. 00781. x
28. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571
29. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000;6:3056-3061
30. Zhang D, Pier T, McNeel DG, Wilding G, Friedl A. Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels-A pharmacodynamic study. Invest New Drugs. 2007;25:49-55. doi: 10. 1007/s10637-006-9013-8
31. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1-13. doi: 10. 1016/j. nbd. 2003. 12. 016
32. Cambier S, Gline S, Mu D, Collins R, Araya J, Dolganov G, Einheber S, Boudreau N, Nishimura SL. Integrin alpha(v)beta8-mediated activation of transforming growth factor-beta by perivascular astrocytes: an angiogenic control switch. Am J Pathol. 2005;166:1883-1894
33. Scaffidi AK, Petrovic N, Moodley YP, Fogel-Petrovic M, Kroeger KM, Seeber RM, Eidne KA, Thompson PJ, Knight DA. alpha(v)beta(3) Integrin interacts with the transforming growth factor beta (TGFbeta) type II receptor to potentiate the proliferative effects of TGFbeta1 in living human lung fibroblasts. J Biol Chem. 2004;279:37726-37733. doi: 10. 1074/jbc. M403010200
34. Wipff PJ, Hinz B. Integrins and the activation of latent transforming growth factor beta1-an intimate relationship. Eur J Cell Biol. 2008;87:601-615. doi: 10. 1016/j. ejcb. 2008. 01. 012
35. Tiller H, Kamphuis MM, Flodmark O, Papadogiannakis N, David AL, Sainio S, Koskinen S, Javela K, Wikman AT, Kekomaki R, Kanhai HH, Oepkes D, Husebekk A, Westgren M. Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open. 2013;3:. doi: 10. 1136/bmjopen-2012-002490
36. Pooh RK, Kurjak A. Fetal brain vascularity visualized by conventional 2D and 3D power doppler technology. DSJUOG. 2010;4:249-258